Subdermal implants of different steroidal compounds for treatment of endocrinological disorders.
Various types of steroid-containing implants were used in the treatment of benign prostatic hypertrophy, congestive prostatitis, and hypogonadism. 2 Silastic capsules, each containing 22-23 mg of ethinyl estradiol, were inserted subcutaneously in 5 men with benign prostatic hypertrophy. A decline in testosterone levels to less than 1 ng/ml was attained within 6 months following insertion. 6-8 Silastic capsules containing 21-23 mg each of testosterone were implanted in 15 men: 2 castrates and 13 hypogonadals. Testosterone levels increased initially, reaching the highest level at 3 months. Thereafter, the testosterone concentrations declined but remained slightly above pretreatment levels at 9 months. In a group of 9 subjects, 7 men with hypogonadism and 2 women with hypernephroma were treated with 2 rods, each containing approximately 200 mg testosterone propionate. Testosterone concentrations showed initial rises but did not remain elevated. 12 male subjects, 6 with congestive prostatis and 6 with benign prostatic hypertrophy, were treated with a combination of 3 levonorgestrel rods and 3 estrone rods. Each rod contained 40 mg of steroid. This regimen had a therapeutic effect but was only partially successful in inhibiting spermatogenesis.
D000328:Adult; D000368:Aged; D004343:Drug Implants; D004970:Estrone / Q000008:administration & dosage; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011472:Prostatitis / Q000188:drug therapy*; D013256:Steroids / Q000008:administration & dosage*; D013739:Testosterone / Q000008:administration & dosage
D004343:Drug Implants; D013256:Steroids; D004970:Estrone; D009644:Norgestrel; D013739:Testosterone; D004997:Ethinyl Estradiol